Targeting epidermal growth factor receptor—are we missing the mark?-Reference-Cited by-同舟云学术

Targeting epidermal growth factor receptor—are we missing the mark?

Published:2003-07 Issue:9377 Volume:362 Page:62-64
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Dancey Janet E,Freidlin Boris

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC);Cunningham;Proc Am Soc Clin Oncol,2003

2. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents;Ciardiello;Drugs,2000

3. Severe acute interstitial pneumonia and gefitinib;Inoue;Lancet,2003

4. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types;Baselga;J Clin Oncol,2002

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Targeting of Cancer Cells;Abeloff's Clinical Oncology;2020

2. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board;Frontiers in Oncology;2019-08-23

3. SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity;Molecular Oncology;2019-07-10

4. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo;Acta Biomaterialia;2019-06

5. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials;Journal of Cancer;2019